RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report) saw a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 6,800 shares, a growth of 325.0% from the October 31st total of 1,600 shares. Approximately 0.5% of the shares of the stock are sold short. Based on an average daily volume of 29,300 shares, the short-interest ratio is presently 0.2 days.
RedHill Biopharma Price Performance
NASDAQ RDHL traded up $0.15 during trading hours on Wednesday, hitting $8.06. The company had a trading volume of 5,525 shares, compared to its average volume of 110,339. RedHill Biopharma has a fifty-two week low of $6.34 and a fifty-two week high of $82.00. The business has a fifty day simple moving average of $8.18 and a 200-day simple moving average of $133.09.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on shares of RedHill Biopharma in a research note on Saturday, August 24th. They set a “hold” rating for the company.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Featured Articles
- Five stocks we like better than RedHill Biopharma
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- 3 Monster Growth Stocks to Buy Now
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
